GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

NCT04064840 · tracked via the Priya Life Science China tracker

Sponsor

The University of Hong Kong

Phase

Phase 3

Started

2019-09-01

Last updated

2026-05-15

Condition(s) studied

Subfertility

Investigational drug(s) / intervention(s)

IVF: Decapeptyl and hCGFET: DecapeptylIVF: hCG and normal salineFET: Normal Saline

IVF: Decapeptyl and hCG: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.

FET: Decapeptyl: On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.

IVF: hCG and normal saline: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.

FET: Normal Saline: On the day of FET, normal saline will be injected subcutaneously.

Study summary

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

42 Years

Healthy volunteers

IVF Inclusion criteria: \- Women aged \<43 years at the time of IVF treatment Exclusion criteria: * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated * Women at risk of OHSS FET Inclusion criteria: * Women aged \<43 years at the time of IVF treatment * Replacing early cleavage embryos or blastocysts after thawing * FET in natural cycles Exclusion criteria: * Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated

Primary outcome measure(s)

Live birth rate — after 22 weeks
delivery after 22 weeks

Trial sites (1)

Facility	City	Region	Status
Department of Obstetrics and Gynaecology	Hong Kong	Hong Kong	Recruiting

More The University of Hong Kong trials in China

The "Quit-for-Kids" Project: to Increase Abstinence and Protect Children From Tobacco Smoke Exposure Recruiting

Smartphone App for Non-alcoholic Fatty Liver Disease Active, not recruiting

The Application of Somatosensory Interactive Pelvic Floor Muscle Training for Stress Urinary Incontinence in Men Underwent Radical Prostatectomy Recruiting

WeChat-Based Digital Therapy to Improve Fluid Intake in Kidney Stone Patients: Study Protocol Enrolling by invitation

Camouflaged WeChat-based Intervention for Abused Women Starting soon

Other trials for the same condition

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04064840 on ClinicalTrials.gov ↗ ← All trials in China